To explore possible implications of XDGs in preclinical drug development, a series of gene set enrichment or association analyses were conducted with different cancer-related gene categories (Table S8), targetable protein kinases (Table S9), and previously reported gene signatures defining various ovarian cancer molecular subtypes (Table S10). This evidence concerns the gene WEE1 and ovarian carcinoma.